DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000097:blood* / Q000134:cerebrospinal fluid; D000818:Animals; D001322:Autoanalysis; D002648:Child; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000097:blood* / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D004422:Dystonia Musculorum Deformans / Q000097:blood / Q000134:cerebrospinal fluid; D005215:Fasting; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D008715:Methionine / Q000134:cerebrospinal fluid; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood* / Q000134:cerebrospinal fluid / Q000188:drug therapy; D011392:Proline / Q000097:blood; D051381:Rats; D013997:Time Factors
D000596:Amino Acids; D004295:Dihydroxyphenylalanine; D011392:Proline; D008715:Methionine